Dr. Ventrapati Pradeep

Dr. Pradeep is a well - known Radiation Oncologist in Visakhapatnam with a professional experience of three years. He provides excellent treatments like Proton Therapy, Tomotherapy, Three-Dimensional Conformal Radiation Oncology (3D-CRT), Intensity-Modulated Radiation Oncology (IMRO), Image Guided Radiation Oncology (IGRO), Stereotactic Radiosurgery (SRS), Radionuclide Therapy (RNT) etc..

The doctor is a life member of the Association of Radiation Oncologists of India since 2014.

• - Selected for National Talent Search Examination Scholarship
• - Secured 49th rank in Engineering and Medical Common Entrance Test (EAMCET) in Andhra Pradesh
• - Secured all India 80th rank in MD/MS entrance exam conducted by All India Institute of Medical Sciences, New Delhi
• - Secured all-India 80th rank in MD/MS entrance exam conducted by All India Institute of Medical Sciences, New Delhi
• - Awarded 1st prize in Mumbai Hematology Group Quarterly Conference for Presentation on Acute Leukemia with FGFR Translocation
• - Presented TMH Data on Young Breast Cancer in TAYCON 2020 conference and Women’s Cancer Initiative (WCI) Conference
• - Wrote a Chapter titled “Chemotherapy related Oral Complications and Management” For textbook of Dental Sciences
• - Wrote a Chapter on “Role of PDL-1 in NSCLC and other solid tumors” for TMH EBM book 2021

• - Life Member, Association of Radiation Oncologists of India (AROI), ID: LM 2244.

• - Anaplastic hemangiopericytoma of eyelid: An unusual location , J Cancer Res Ther. 2017 Jan-Mar;13(1):145-147
• - Early survival outcomes in stage I-III operated colon cancer patients from a low prevalence, lower-middle income country: The Indian experience. Journal of Clinical Oncology 2018 36:4_suppl, 857-857
• - Pattern of microbial organisms in radiation induced mucositis and dermatitis in head and neck squamous cell carcinoma (HNSCC) treated with radiation (RT)/chemo radiation (CTRT). Journal of Clinical Oncology 2014 32:31_suppl, 210-210
• - Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G, Khaddar S, Gupta K, Rathinasamy N, Srinivas S, Agrawal A, Ventrapati P, Prabhash K. A real-world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Med. 2021 Feb 16. doi: 10.1002/cam4.3617. Epub ahead of print. PMID: 33591635
• - Bondili SK, Bagal B, Zawar A, Ventrapati P, Thorat J, Gokarn A, et al. Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center. JCO Glob Oncol. 2021 Dec;(7):361–7.
• - Bondili SK, Bagal B, Zawar A, Ventrapati P, Thorat J, Gokarn A, et al. Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center. JCO Glob Oncol. 2021 Dec;(7):361–7.
• - Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, et al. A real-world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Med. 2021;10(5):1525–34.
• - Pradeep V. Time for cancer to be designated a notifiable disease in India. Cancer Res Stat Treat. 2021 Jan 1;4(1):153.
• - Pradeep V. Time for cancer to be designated a notifiable disease in India. Cancer Res Stat Treat. 2021 Jan 1;4(1):153.
• - Ventrapati P. Old targets, new bullets, nursing fresh hope. Cancer Res Stat Treat. 2021 Oct 1;4(4):788.